Risk Factors and Treatment Strategies for Myositis Autoantibodies

This chapter explores the impact of specific myositis autoantibodies on the development of interstitial lung disease in systemic sclerosis patients, emphasizing the importance of early detection through laboratory markers and diagnostic tests like pulmonary function tests and echocardiograms. It also discusses the challenges in treating systemic sclerosis patients due to the lack of a universal disease-modifying therapy, highlighting specific treatments such as microfennelate for skin thickening. Additionally, the management of rainodes in systemic sclerosis patients, including seasonal adjustments to medication and symptomatic treatments, is addressed in the conversation.